Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2016-06-02

FDA Approved: ICLUSIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

FDA approved a supplemental application for ICLUSIG (ponatinib hydrochloride) from Takeda Pharmaceuticals America, Inc. The approval updates the product labelin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Iclusig (ponatinib)

Snippet

SUPPL AP for ICLUSIG (PONATINIB HYDROCHLORIDE)